about
Genetic determinants and potential therapeutic targets for pancreatic adenocarcinomaAlterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma.K-ras mutational status in cytohistological tissue as a molecular marker for the diagnosis of pancreatic cancer: a systematic review and meta-analysisTargeting of C-terminal binding protein (CtBP) by ARF results in p53-independent apoptosis.Genetic mutations associated with cigarette smoking in pancreatic cancerGermline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancersK-ras and Dpc4 mutations in chronic pancreatitis: case seriesSTK11/LKB1 Peutz-Jeghers gene inactivation in intraductal papillary-mucinous neoplasms of the pancreasp8 inhibits the growth of human pancreatic cancer cells and its expression is induced through pathways involved in growth inhibition and repressed by factors promoting cell growthGenetic abnormalities in pancreatic cancerGenetic alterations in pancreatic carcinomaWhat is the origin of pancreatic adenocarcinoma?Pancreatic Cancer from Molecular Pathways to Treatment OpinionMolecular targets for the treatment of pancreatic cancer: Clinical and experimental studiesGenomic alterations in pancreatic cancer and their relevance to therapyMouse models of pancreatic cancerRegulation of pancreatic function by connective tissue growth factor (CTGF, CCN2)Chronic Pancreatitis and Pancreatic CancerExploiting inflammation for therapeutic gain in pancreatic cancerThe crystal structure of the tumor suppressor protein pp32 (Anp32a): Structural insights into Anp32 family of proteinsDPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer?Therapeutic potential of targeting acinar cell reprogramming in pancreatic cancerGenetic factors affecting patient responses to pancreatic cancer treatmentPancreatic cancer, treatment options, and GI-4000Targeted destruction of the orchestration of the pancreatic stroma and tumor cells in pancreatic cancer cases: molecular basis for therapeutic implicationsThe tumor suppressor gene Smad4/Dpc4 is required for gastrulation and later for anterior development of the mouse embryoNovel pancreatic cancer cell lines derived from genetically engineered mouse models of spontaneous pancreatic adenocarcinoma: applications in diagnosis and therapyCommon activation of canonical Wnt signaling in pancreatic adenocarcinoma.In vivo quantitative microvasculature phenotype imaging of healthy and malignant tissues using a fiber-optic confocal laser microprobe.A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancerInflammation and Epithelial-Mesenchymal Transition in Pancreatic Ductal Adenocarcinoma: Fighting Against Multiple OpponentsPancreatic cancer: pathobiology, treatment options, and drug delivery.Epigenetic changes associated with neoplasms of the exocrine and endocrine pancreas.The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53.Diabetes and exocrine pancreatic insufficiency in E2F1/E2F2 double-mutant mice.KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma.Comparative analysis of clinicopathological correlations of cyclooxygenase-2 expression in resectable pancreatic cancer
P2860
Q21129230-F3F2ACAF-8568-47C9-AADF-4A7E178130DFQ21261876-C6FB8825-32FE-435C-B629-DB8330FAB23FQ21284688-23BB19D8-DF59-43CC-AA13-618C8B2971BAQ24548025-9EB5A75F-150A-4DCB-B526-0C5210EA065CQ24658185-FC21CF9C-C2EC-486C-93F3-522386E241C5Q24671334-6829B46E-5180-412E-9455-E0B7735B75F5Q24676729-E8B7BE2C-CF7D-42FC-B5E1-7A92651A11B3Q24685646-3C465F0C-5608-44F7-AC07-7B37230FAEEDQ24797943-4CFBC50E-9EF5-4F21-898F-32E5A8B79C3CQ24800194-7C37B3D5-BC03-46C0-AE7B-57943480F3C1Q24801465-13489EC7-EDFD-4501-80AD-A634DEECABDDQ24805751-DDF18CD4-C1AD-4890-8332-3CE645468128Q26743482-DADEB2F6-4495-4FDD-B94D-64DE37D5C680Q26774636-5382A8C6-46F7-46EE-87C5-542353B90C7CQ26781443-F157F35E-EF53-4A55-B9AF-70C30A96611FQ26860574-7E6FF088-25E8-4DD1-A56B-6E0208180F1BQ27012580-A368E463-8DDC-4D4C-8015-349CB97F8B7EQ27025915-531FE1CF-97C2-46BF-8F0A-FFDD906C9B22Q27027661-ACD76331-3DEE-481D-9A35-1B9E59085FECQ27645802-5EBFD245-AA8A-4A71-B228-CFC256EB82D4Q27851466-2DA374D5-C9F2-43BC-B89D-1BB766621041Q27851677-3E91096A-684D-40AF-B560-2AEBD488C434Q28066268-FCE689F2-F019-438E-9B4C-F162EDE8D2D4Q28068998-E5772BA2-9D93-438A-89B9-03C0A587AEF3Q28075293-02DA7F53-035D-4C47-A38F-1C3ABF16FD57Q28083814-B7CFEE69-ACBA-45D5-95C6-14F345B6B5CEQ28269990-A92C7D27-8DF4-4820-A6DF-18F260952044Q28512702-A0559EA4-D81E-41CA-8055-FFBDA0F51AE8Q28535288-6A2777B2-7A06-4477-9699-F8DCFB578B86Q33304986-FBB84F0D-F03E-4B07-9D00-0872E20F24F7Q33352468-9B23EF1C-27C3-4425-A197-009AF53907A7Q33394594-E25EA6EC-0875-4261-BEBF-20325B50D917Q33628253-E9D25582-0C50-4B7E-8783-E7994F614FE3Q33704284-5745622D-D0F2-4F29-BB7A-012753D52905Q33749460-F0C55A13-66FE-49BF-B66F-0C928117E475Q33771064-2C057D3B-C333-4299-A303-0B01ED84B77EQ33781484-D396CCC6-91FF-4756-AABD-7E1C7AEF9957Q33784781-F9808DC9-0518-47B2-92DC-346268A62D80Q33790710-4333B90F-53E3-48F6-AA41-8BB0E33D81A0Q33798878-49BFC593-2AAD-4A41-BA31-7BC1EE3751D6
P2860
description
1997 nî lūn-bûn
@nan
1997 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Tumor-suppressive pathways in pancreatic carcinoma.
@ast
Tumor-suppressive pathways in pancreatic carcinoma.
@en
Tumor-suppressive pathways in pancreatic carcinoma.
@nl
type
label
Tumor-suppressive pathways in pancreatic carcinoma.
@ast
Tumor-suppressive pathways in pancreatic carcinoma.
@en
Tumor-suppressive pathways in pancreatic carcinoma.
@nl
prefLabel
Tumor-suppressive pathways in pancreatic carcinoma.
@ast
Tumor-suppressive pathways in pancreatic carcinoma.
@en
Tumor-suppressive pathways in pancreatic carcinoma.
@nl
P2093
P1433
P1476
Tumor-suppressive pathways in pancreatic carcinoma
@en
P2093
Goodman SN
Rozenblum E
P304
P407
P577
1997-05-01T00:00:00Z